Verismo-HLB Innovation Merger to Accelerate KIR-CAR Cancer Treatment

Verismo Therapeutics and HLB Innovation will expedite the clinical advancement of SynKIR-110 and SynKIR-310 for patients with solid tumors and blood cancers, respectively, reinforcing the shared goal of Verismo and HLB Group to promote their groundbreaking KIR-CAR platform for patients globally.

Verismo Therapeutics declared the finalization of a merger, resulting in the company becoming a fully-owned subsidiary of HLB Innovation, a publicly listed firm in South Korea and part of the HLB Group. The merger certificate is anticipated to be submitted soon.

"We are thrilled to take this next step with HLB Innovation as our parent company," said Bryan Kim, CEO of Verismo Therapeutics. "This merger not only strengthens our resources by leveraging HLB Group's dynamic bio-ecosystem, but also enhances our ability to rapidly advance our clinical pipelines. We're confident that with HLB Innovation's backing, Verismo is well-positioned to bring transformative therapies to areas of unmet medical need."

The HLB Group, which has a diverse portfolio that spans biopharma, medical devices, healthcare, lifestyle, and other sectors, previously held a majority stake in Verismo. This merger aligns with HLB Group's strategic commitment to expanding its capabilities in next-generation cell therapies.

The HLB Group, with its varied portfolio covering biopharma, medical devices, healthcare, lifestyle, and additional industries, once owned a majority share in Verismo. This merger supports HLB Group's strategic dedication to enhancing its competencies in next-generation cell treatments.